Thank you for posting , the article is extremely interesting ,...

Thank you for posting , the article is extremely interesting , even through covid they continued with the FDA application ,,shows what can be achieved by a dedicated team

Anivive discovers first-in-class therapeutics for unmet conditions in pets. Anivive has in-licensed the global development and commercialization rights to 5 mid/late stage product candidates and holds exclusive rights to several others. Anivive is currently seeking FDA conditional approval for verdinexor (a canine lymphoma investigational therapeutic) and USDA conditional license for canine Valley Fever investigational vaccine. More than 1,000,000 dogs succumb to canine lymphoma annually and there are over 30,000,000 dogs at risk for Valley Fever in the U.S.

Anivive continues to develop a mid-stage therapeutic for feline infectious peritonitis (FIP). FIP is caused by a feline coronavirus that kills 700,000 cats annually.

The FDA lowered the bar during the Initial Covid 19 outbreak , they were handing out Interim Approvals mainly for repurposed Drugs, Interim Approval is usually from 1 to 3 years and its like an open Phase III where the FDA monitor adverse effects,, those that don't demonstrate vast adverse effects gain FDA approval at the end of their Interim Period...